Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEN Compugen	$1.45 -2.0%	$1.60	$1.13 ▼ $2.66	$132.07M	2.61	265,927 shs	96,988 shs
CTOR Citius Oncology	$1.72 -3.9%	$2.42	$0.55 ▼ $6.19	$140.28M	3	1.59 million shs	277,236 shs
NKTX Nkarta	$2.20 -0.5%	$1.92	$1.31 ▼ $6.63	$156.96M	0.72	594,389 shs	827,367 shs
PLUR Pluri	$5.02 +3.2%	$4.97	$3.33 ▼ $7.13	$38.25M	0.76	8,306 shs	23,115 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEN Compugen	-2.03%	+0.69%	-8.23%	+4.32%	-17.14%
CTOR Citius Oncology	-3.91%	-7.03%	+11.69%	+87.98%	-30.36%
NKTX Nkarta	-0.45%	+9.45%	+20.88%	+26.44%	-57.12%
PLUR Pluri	+5.80%	+3.83%	+0.10%	-3.74%	-9.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEN Compugen	1.9628 of 5 stars	3.5	3.0	2.6	0.0	0.0
CTOR Citius Oncology	1.6495 of 5 stars	3.0	0.0	2.8	1.7	0.0
NKTX Nkarta	2.0525 of 5 stars	3.5	0.0	3.0	1.7	0.6
PLUR Pluri	2.236 of 5 stars	3.5	3.0	1.9	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEN Compugen	3.00	Buy	$4.00	175.86% Upside
CTOR Citius Oncology	2.00	Hold	$3.00	74.42% Upside
NKTX Nkarta	3.00	Buy	$13.60	518.18% Upside
PLUR Pluri	3.00	Buy	$12.00	139.28% Upside

Current Analyst Ratings Breakdown

Latest PLUR, NKTX, CGEN, and CTOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	NKTX Nkarta	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
8/13/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
6/2/2025	PLUR Pluri	Industrial Alliance Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
6/2/2025	PLUR Pluri	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
5/23/2025	CTOR Citius Oncology	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/23/2025	CTOR Citius Oncology	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEN Compugen	$27.86M	4.64	N/A	N/A	$0.56 per share	2.59
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.41 per share	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.04 per share	N/A
PLUR Pluri	$330K	119.60	N/A	N/A	$1.00 per share	5.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEN Compugen	-$14.23M	-$0.22	N/A	N/A	N/A	-87.45%	-34.77%	-16.82%	N/A
CTOR Citius Oncology	N/A	N/A	0.00	∞	N/A	N/A	-51.93%	-22.17%	N/A
NKTX Nkarta	-$108.79M	-$1.48	N/A	N/A	N/A	N/A	-27.74%	-22.38%	N/A
PLUR Pluri	-$20.89M	-$5.53	N/A	∞	N/A	-2,563.29%	-4,191.91%	-85.40%	9/17/2025 (Estimated)

Latest PLUR, NKTX, CGEN, and CTOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	NKTX Nkarta	-$0.37	-$0.31	+$0.06	-$0.31	N/A	N/A
8/6/2025	Q2 2025	CGEN Compugen	-$0.07	-$0.08	-$0.01	-$0.08	$3.95 million	$1.26 million
5/19/2025	Q1 2025	CGEN Compugen	-$0.06	-$0.08	-$0.02	-$0.08	$3.70 million	$2.28 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A
PLUR Pluri	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEN Compugen	N/A	4.74	4.74
CTOR Citius Oncology	0.12	0.35	0.05
NKTX Nkarta	N/A	15.67	14.48
PLUR Pluri	51.65	4.81	4.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEN Compugen	12.22%
CTOR Citius Oncology	70.52%
NKTX Nkarta	80.54%
PLUR Pluri	16.59%

Insider Ownership

Company	Insider Ownership
CGEN Compugen	9.50%
CTOR Citius Oncology	4.57%
NKTX Nkarta	8.40%
PLUR Pluri	25.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEN Compugen	70	89.24 million	80.76 million	Optionable
CTOR Citius Oncology	N/A	78.37 million	74.79 million	N/A
NKTX Nkarta	140	71.03 million	65.00 million	Optionable
PLUR Pluri	150	7.87 million	5.83 million	Optionable

PLUR, NKTX, CGEN, and CTOR Headlines

Recent News About These Companies

Pluri Inc. director not re-elected, Nasdaq compliance cure period granted

July 5, 2025 | investing.com

Insider Buying: Pluri Inc. (NASDAQ:PLUR) Director Purchases 976,139 Shares of Stock

July 2, 2025 | insidertrades.com

Alliance Global Partners Initiates Coverage of Pluri (PLUR) with Buy Recommendation

June 2, 2025 | msn.com

Pluri Inc. reschedules 2025 annual meeting

May 27, 2025 | investing.com

BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

May 27, 2025 | prnewswire.com

Brainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plans

May 19, 2025 | msn.com

Pluri Inc.: Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.

May 16, 2025 | finanznachrichten.de

Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion

May 16, 2025 | tmcnet.com

Pluri: Fiscal Q3 Earnings Snapshot

May 13, 2025 | timesunion.comT

Pluri Inc. acquires majority stake in Kokomodo Ltd.

April 30, 2025 | uk.investing.com

Pluri acquires 71% stake in Kokomodo

April 29, 2025 | foodbusinessnews.netF

Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.

April 28, 2025 | globenewswire.com

Pluri Inc. enters agreement, issues pre-funded warrants

April 27, 2025 | investing.com

Ukraine gains access to Israeli anti-radiation drug amid nuclear threats

April 21, 2025 | msn.com

Ukraine prepares for nuclear emergency - Israel to help save thousands

April 21, 2025 | msn.com

In case of a nuclear event, Ukraine to use Israeli placenta-based emergency treatment

April 20, 2025 | msn.com

Innovative Treatment Aims to Protect Ukrainians from Nuclear Radiation Threat

April 17, 2025 | themunicheye.comT

Pluri announces USPTO issued patent covering its immune cell expansion tech

April 12, 2025 | markets.businessinsider.com

Pluri’s immune cell expansion technologies gain patents

April 11, 2025 | finance.yahoo.com

Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel

April 10, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLUR, NKTX, CGEN, and CTOR Company Descriptions

Compugen NASDAQ:CGEN

$1.45 -0.03 (-2.03%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.44 0.00 (-0.34%)

As of 08/14/2025 04:47 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Citius Oncology NASDAQ:CTOR

$1.72 -0.07 (-3.91%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.74 +0.02 (+1.16%)

As of 08/14/2025 07:55 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Nkarta NASDAQ:NKTX

$2.20 -0.01 (-0.45%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.20 0.00 (0.00%)

As of 08/14/2025 07:32 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Pluri NASDAQ:PLUR

$5.01 +0.16 (+3.19%)

Closing price 08/14/2025 03:54 PM Eastern

Extended Trading

$5.02 +0.00 (+0.10%)

As of 08/14/2025 05:07 PM Eastern

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time